139 related articles for article (PubMed ID: 15325667)
21. [A comparison of intra-arterial chemoembolization and infusion chemotherapy for liver metastases of breast cancer].
Yayoi E; Furukawa J; Sekimoto M; Kinuta M; Tateishi H; Maruyama H; Okamura J; Ooi H
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1519-22. PubMed ID: 7574748
[TBL] [Abstract][Full Text] [Related]
22. [A case of breast cancer with multiple organ metastases responding remarkably to combination therapy of CAF (cyclophosphamide, adriamycin and 5-FU), 5'-DFUR and MPA (medroxyprogesterone acetate)].
Maruyama S; Okumoto T; Kawasaki K; Ino H; Kanaya Y; Otani J; Yokoyama N; Soda M
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2235-8. PubMed ID: 11142168
[TBL] [Abstract][Full Text] [Related]
23. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
[TBL] [Abstract][Full Text] [Related]
24. [A case of complete remission of breast cancer with bilateral multiple lung metastases by combination therapy of MPA, THP, CPM and 5-FU].
Kusama M; Kimura K; Koyanagi Y; Kaise H; Arima M; Satoh Y; Murata J; Matsunaga T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):521-4. PubMed ID: 8452389
[TBL] [Abstract][Full Text] [Related]
25. Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer.
Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
Anticancer Res; 1996; 16(4A):2069-72. PubMed ID: 8712744
[TBL] [Abstract][Full Text] [Related]
26. Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome.
Gentilini O; Intra M; Gandini S; Peruzzotti G; Winnikow E; Luini A; Veronesi P; Galimberti V; Goldhirsch A; Veronesi U
J Surg Oncol; 2006 Oct; 94(5):375-9. PubMed ID: 16967462
[TBL] [Abstract][Full Text] [Related]
27. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
28. [Advanced breast cancer with multiple bone metastases successfully treated with combined chemoendocrine-therapy of CEF (cyclophosphamide, epirubicin, 5-fluorouracil) and 5'-DFUR (5'-deoxy-5-fluorouridine) + MPA (medroxyprogesterone acetate)--a case report].
Fukuda Y; Hirao S; Koyama I; Takatori H; Terakura M; Mayumi K; Tsukazaki Y; Kinoshita H
Gan To Kagaku Ryoho; 2001 Feb; 28(2):217-20. PubMed ID: 11242649
[TBL] [Abstract][Full Text] [Related]
29. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
30. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
[TBL] [Abstract][Full Text] [Related]
31. [A case of breast cancer patient of CAF (cyclophosphamide, adriamycin, 5-fluorouracil) resistant lung metastasis with remarkable response to reverse drug-resistance by toremifene].
Kusama M; Kaise H; Nakayama S; Ohta D; Aoki T; Koyanagi Y
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1171-5. PubMed ID: 10431584
[TBL] [Abstract][Full Text] [Related]
32. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
[TBL] [Abstract][Full Text] [Related]
33. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
35. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
[TBL] [Abstract][Full Text] [Related]
36. [A case of locally advanced breast cancer successfully treated with FEC (100) followed by weekly paclitaxel].
Tokunaga Y; Takahashi K; Saito T
Gan To Kagaku Ryoho; 2005 Sep; 32(9):1307-9. PubMed ID: 16184929
[TBL] [Abstract][Full Text] [Related]
37. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Green MC; Buzdar AU; Smith T; Ibrahim NK; Valero V; Rosales MF; Cristofanilli M; Booser DJ; Pusztai L; Rivera E; Theriault RL; Carter C; Frye D; Hunt KK; Symmans WF; Strom EA; Sahin AA; Sikov W; Hortobagyi GN
J Clin Oncol; 2005 Sep; 23(25):5983-92. PubMed ID: 16087943
[TBL] [Abstract][Full Text] [Related]
38. [Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report].
Izumi M; Iino Y; Yokoe T; Inoue T; Yamada T; Kobayashi I; Andoh T; Yokota T; Iijima T; Morishita Y
Gan To Kagaku Ryoho; 1994 Feb; 21(2):265-8. PubMed ID: 8311500
[TBL] [Abstract][Full Text] [Related]
39. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
40. [A case of recurrent breast cancer with multiple liver metastases responding to combination therapy of capecitabine and MPA].
Konishi K; Hasegawa N; Kawabata M; Abeshima S; Ichimura T; Kaneko H; Nakayama T
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1689-91. PubMed ID: 17940392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
